Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
SeekingAlpha4 gün öncePFE
Take Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC’s ‘Final Trades’
Take-Two Interactive Software, on Aug. 7, reported adjusted earnings were 35 cents per share, topping the analyst consensus of 33 cents.
Benzinga4 gün öncePFE
BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.
SeekingAlpha7 gün öncePFE
Hesai Says Co Selected By NVIDIA As Lidar Partner For NVIDIA DRIVE Hyperion 10
Benzinga7 gün öncePFE
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Benzinga7 gün öncePFE
FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
Benzinga8 gün öncePFE
FDA Approves Drug To Treat HIV Infection in Newborns
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns
Benzinga10 gün öncePFE
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector. Top analysts & recent news on PRGO, PFE, BMY.
Benzinga10 gün öncePFE
This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion
After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains.
Yahoo13 gün öncePFE
Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players
The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers
Yahoo13 gün öncePFE
2 Reasons to Watch PFE and 1 to Stay Cautious
Pfizer has been treading water for the past six months, recording a small return of 2.6% while holding steady at $27.76. The stock also fell short of the S&P 500’s 12.7% gain during that period.
Yahoo13 gün öncePFE
Pfizer: Patient Investors Will Be Rewarded
Pfizer remains undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. Read more on PFE stock here.
SeekingAlpha14 gün öncePFE
The 9% Portfolio That Retires Your Paycheck
Build a durable 9% yield retirement income portfolioâdividends to cover expenses without forced sales. Read the full analysis here.
SeekingAlpha17 gün öncePFE
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
NEW YORK & LYON, France, August 14, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application.
Yahoo21 gün öncePFE
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
Benzinga21 gün öncePFE
Valneva Q2 Earnings Call Highlights
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer. CEO Thomas Lingelbac
Yahoo21 gün öncePFE
Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success
Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality.Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ® (Pfizer), withdrawal of ROCTAVIA
Yahoo21 gün öncePFE
How Pfizer’s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story
In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50–US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer’s autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology...
Yahoo22 gün öncePFE
Pfizer CEO Buys $1 Million of Stock
Albert Bourla adds 38,000 shares.
Yahoo22 gün öncePFE